Login:
Share:
Email Facebook Twitter

SAR Share Chat - RSS Feed

Sareum Share Chat (SAR)



Share Price: 0.475Bid: 0.45Ask: 0.50Change: 0.00 (0.00%)No Movement on Sareum
Spread: 0.05Spread as %: 11.11%Open: 0.475High: 0.475Low: 0.475Yesterday’s Close: 0.475


Share Discussion for Sareum (SAR)


Thread ViewThread View
Please Login or Register to post messages
Posts per page:


Chrisatrdg
Posts: 78
Observation
Opinion:Strong Buy
Price:0.60
cheap as chips
28 Jan '14
Hi All - I only have a small number of shares in SAR as I am primarily in Summit plc and like many others I am currently showing a paper loss on SAR and also I have a realised loss but I agree with PCS1954 deals are only achieved after strict due diligence. In my opinion these shares are a 'cheap as chips' and I only wish I had funds to buy more.
Onwards and upwards.
 
PCS1954
Posts: 950
Off Topic
Opinion:Hold
Price:0.60
View Thread (2)
Good morning all
28 Jan '14
just a thought - no matter what your take on the current scenario with sp, news etc.. - I think you will agree that BACIT would have carried out a "good old reekie" on TM and SAR before commiting themselves to co-development for CHK1 - would have been aware of the placing and China - so whilst , we all natter on with only what is front of our eyes by way of rns's and the sp - imvho there is news to be had and who knows it maybe sooner than we think.

As a long term holder I sit and wait GLA
Num4
Posts: 526
Off Topic
Opinion:No Opinion
Price:0.60
No matter
28 Jan '14
What Link you read on google you will be encouraged by the comments and be happy with your investment. Until you look at the share price and realise, this is gash. All this talk but no value, something we have been promised for years, post Dec 2012 AGM morning announcement the market has taken a different perspective on Tim and Sareum, now I think it will take a cold hard cash injection of millions and solid news of compounds IN trials, not working towards or advancing into or any other assumption of progression.

Tim has got assumptions wrong on a number of occasions, remember projected cash flow from accounts back in 2011 or 2012, 4million rings a bell for 2013.
Hopefully he has just been unlucky, like a lot of us with this share.
We all deserve a change in luck and I hope it comes Q1 2014.
AndytheMKDon
Posts: 7,076
Off Topic
Opinion:No Opinion
Price:0.60
View Thread (2)
Fork
28 Jan '14
A member for three weeks and 500+ posts most of them the same. What did you do before you became an expert in January.. By the way an ex is a has-been and spurt is a drip under pressure.. Didn’t your mother ever tell you nobody likes a smart ärse.. ??
BOOKMAN
Posts: 660
Off Topic
Opinion:No Opinion
Price:0.60
dummy sell of
28 Jan '14
500,500k 54.9
johnygreenfeet
Posts: 1,036
Off Topic
Opinion:No Opinion
Price:0.60
fork
28 Jan '14
lets hope so
everybodyelse
Posts: 177
Off Topic
Opinion:No Opinion
Price:0.60
CRT Link
28 Jan '14
"...it is expected that the drug candidate will be taken into clinical development at The Royal Marsden NHS Foundation Trust."

On Chk1 3rd paragraph down.
everybodyelse
Posts: 177
Off Topic
Opinion:No Opinion
Price:0.60
View Thread (2)
RE: Just a reminder
27 Jan '14
Thanks for the reminder. Incidentally this is all Fork needed to post to hold up his 4 month news due, but all we get is repeat posts. Sometimes we just need to be reminded about hard facts, and linked to them, to keep people happy.
kazimira
Posts: 59
Off Topic
Opinion:No Opinion
Price:0.60
View Thread (2)
Just a reminder
27 Jan '14
of the Chk1 programme joint development agreement back in September, when SPEED was of the essence:

http://www.cancerresearchuk.org/about-us/cancer-news/press-release/crt-pioneer-fund-bacit-and-sareum-enter-agreement-to-fund-development-of-drugs-to-treat-cancers-including-pancreatic-bowel-and-lung

Dr Tim Mitchell, CEO of Sareum, said: “The funding which we are announcing today will enable the project to move SWIFTLY towards, and potentially into Phase I clinical trials"

Professor Paul Workman, deputy chief executive of The Institute of Cancer Research: “Our CHK1 inhibitor has exciting potential both as a cancer treatment in its own right and also as a drug to boost the effectiveness of chemotherapy and radiotherapy. All the partners are EAGER to EXPEDITE the drug candidate into clinical trials AS QUICKLY AS POSSIBLE because of the potential to treat large numbers of cancer patients with this approach.”



Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs

Sign up for Live Prices


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.